Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...

(Reuters) -Cassava Sciences on Monday said its experimental Alzheimer's disease drug did not meet the main or secondary goals ...

A decade ago, researchers introduced a new model for studying Alzheimer's disease. Known as "Alzheimer's in a dish," the ...

A future treatment for Alzheimer disease may involve a nasal spray. Researchers at Università Cattolica and Fondazione ...

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

Anavex Life Sciences (AVXL) stock rises 10% in premarket as company submits EU marketing application for Alzheimer's drug ...

Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in ...

While there is no cure for Alzheimer's disease, drug treatments aimed at slowing disease progression and alleviating symptoms ...

Coverage would include diagnostic testing to determine appropriate treatments, as well as prescribed treatments or ...

There's no cure for this disease, but now there is some hope for people and their families who are battling the illness in ...